Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma

Impact on vascular endothelial growth factor expression in hypoxia

Sutapa Sinha, Shamit Dutta, Kaustubh Datta, Asish K. Ghosh, Debabrata Mukhopadhyay

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

TIS11B belongs to a group of RNA-binding proteins (including TIS11/ tristetraprolin and TIS11D) that share characteristic tandem CCCH-type zinc-finger domains and can be rapidly induced by multiple stimuli. TIS11B has been shown to regulate vascular endothelial growth factor (VEGF) mRNA stability in adrenocorticotropic hormone-stimulated primary adrenocortical cells. TIS11B has also been documented as a negative regulator of VEGF during development, but nothing has yet been reported in the context of human cancers. The Von Hippel-Lindau (VHL) tumor suppressor protein regulates VEGF gene expression at both the transcriptional and post-transcriptional levels in normoxia. However, whether it can do so in hypoxia is still unclear. Here, we report a unique regulatory function of VHL in VEGF expression in hypoxia that is mediated through modulation of TIS11B protein levels in renal cancer cells. In normoxia, we detected increased expression of the microRNA hsa-miR-29b in the VHL-overexpressing renal cancer cell line 786-O. We also show that this increased expression of hsa-miR-29b decreased TIS11B protein expression by post-transcriptional regulation in normoxia. In contrast, in hypoxia, increased TIS11B expression paralleled an increased TIS11B mRNA stability in VHL-overexpressing 786-O cells. This VHL-mediated TIS11B up-regulation in hypoxia may be important for TIS11Bregulated gene expression: we observed a down-regulation of VEGFmRNAin hypoxia in VHL-overexpressing cells compared with parental 786-O cells, and this effect was reversible by silencing TIS11B expression.

Original languageEnglish (US)
Pages (from-to)32610-32618
Number of pages9
JournalJournal of Biological Chemistry
Volume284
Issue number47
DOIs
StatePublished - Nov 20 2009

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Genes
Cells
Gene expression
RNA Stability
Von Hippel-Lindau Tumor Suppressor Protein
Tristetraprolin
Messenger RNA
RNA-Binding Proteins
Gene Expression
MicroRNAs
Adrenocorticotropic Hormone
Kidney Neoplasms
Zinc Fingers
Zinc
Proteins
Modulation
Up-Regulation
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma : Impact on vascular endothelial growth factor expression in hypoxia. / Sinha, Sutapa; Dutta, Shamit; Datta, Kaustubh; Ghosh, Asish K.; Mukhopadhyay, Debabrata.

In: Journal of Biological Chemistry, Vol. 284, No. 47, 20.11.2009, p. 32610-32618.

Research output: Contribution to journalArticle

@article{33229cd9bc7d4426aff5b6151e2c4281,
title = "Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: Impact on vascular endothelial growth factor expression in hypoxia",
abstract = "TIS11B belongs to a group of RNA-binding proteins (including TIS11/ tristetraprolin and TIS11D) that share characteristic tandem CCCH-type zinc-finger domains and can be rapidly induced by multiple stimuli. TIS11B has been shown to regulate vascular endothelial growth factor (VEGF) mRNA stability in adrenocorticotropic hormone-stimulated primary adrenocortical cells. TIS11B has also been documented as a negative regulator of VEGF during development, but nothing has yet been reported in the context of human cancers. The Von Hippel-Lindau (VHL) tumor suppressor protein regulates VEGF gene expression at both the transcriptional and post-transcriptional levels in normoxia. However, whether it can do so in hypoxia is still unclear. Here, we report a unique regulatory function of VHL in VEGF expression in hypoxia that is mediated through modulation of TIS11B protein levels in renal cancer cells. In normoxia, we detected increased expression of the microRNA hsa-miR-29b in the VHL-overexpressing renal cancer cell line 786-O. We also show that this increased expression of hsa-miR-29b decreased TIS11B protein expression by post-transcriptional regulation in normoxia. In contrast, in hypoxia, increased TIS11B expression paralleled an increased TIS11B mRNA stability in VHL-overexpressing 786-O cells. This VHL-mediated TIS11B up-regulation in hypoxia may be important for TIS11Bregulated gene expression: we observed a down-regulation of VEGFmRNAin hypoxia in VHL-overexpressing cells compared with parental 786-O cells, and this effect was reversible by silencing TIS11B expression.",
author = "Sutapa Sinha and Shamit Dutta and Kaustubh Datta and Ghosh, {Asish K.} and Debabrata Mukhopadhyay",
year = "2009",
month = "11",
day = "20",
doi = "10.1074/jbc.M109.058065",
language = "English (US)",
volume = "284",
pages = "32610--32618",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "47",

}

TY - JOUR

T1 - Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma

T2 - Impact on vascular endothelial growth factor expression in hypoxia

AU - Sinha, Sutapa

AU - Dutta, Shamit

AU - Datta, Kaustubh

AU - Ghosh, Asish K.

AU - Mukhopadhyay, Debabrata

PY - 2009/11/20

Y1 - 2009/11/20

N2 - TIS11B belongs to a group of RNA-binding proteins (including TIS11/ tristetraprolin and TIS11D) that share characteristic tandem CCCH-type zinc-finger domains and can be rapidly induced by multiple stimuli. TIS11B has been shown to regulate vascular endothelial growth factor (VEGF) mRNA stability in adrenocorticotropic hormone-stimulated primary adrenocortical cells. TIS11B has also been documented as a negative regulator of VEGF during development, but nothing has yet been reported in the context of human cancers. The Von Hippel-Lindau (VHL) tumor suppressor protein regulates VEGF gene expression at both the transcriptional and post-transcriptional levels in normoxia. However, whether it can do so in hypoxia is still unclear. Here, we report a unique regulatory function of VHL in VEGF expression in hypoxia that is mediated through modulation of TIS11B protein levels in renal cancer cells. In normoxia, we detected increased expression of the microRNA hsa-miR-29b in the VHL-overexpressing renal cancer cell line 786-O. We also show that this increased expression of hsa-miR-29b decreased TIS11B protein expression by post-transcriptional regulation in normoxia. In contrast, in hypoxia, increased TIS11B expression paralleled an increased TIS11B mRNA stability in VHL-overexpressing 786-O cells. This VHL-mediated TIS11B up-regulation in hypoxia may be important for TIS11Bregulated gene expression: we observed a down-regulation of VEGFmRNAin hypoxia in VHL-overexpressing cells compared with parental 786-O cells, and this effect was reversible by silencing TIS11B expression.

AB - TIS11B belongs to a group of RNA-binding proteins (including TIS11/ tristetraprolin and TIS11D) that share characteristic tandem CCCH-type zinc-finger domains and can be rapidly induced by multiple stimuli. TIS11B has been shown to regulate vascular endothelial growth factor (VEGF) mRNA stability in adrenocorticotropic hormone-stimulated primary adrenocortical cells. TIS11B has also been documented as a negative regulator of VEGF during development, but nothing has yet been reported in the context of human cancers. The Von Hippel-Lindau (VHL) tumor suppressor protein regulates VEGF gene expression at both the transcriptional and post-transcriptional levels in normoxia. However, whether it can do so in hypoxia is still unclear. Here, we report a unique regulatory function of VHL in VEGF expression in hypoxia that is mediated through modulation of TIS11B protein levels in renal cancer cells. In normoxia, we detected increased expression of the microRNA hsa-miR-29b in the VHL-overexpressing renal cancer cell line 786-O. We also show that this increased expression of hsa-miR-29b decreased TIS11B protein expression by post-transcriptional regulation in normoxia. In contrast, in hypoxia, increased TIS11B expression paralleled an increased TIS11B mRNA stability in VHL-overexpressing 786-O cells. This VHL-mediated TIS11B up-regulation in hypoxia may be important for TIS11Bregulated gene expression: we observed a down-regulation of VEGFmRNAin hypoxia in VHL-overexpressing cells compared with parental 786-O cells, and this effect was reversible by silencing TIS11B expression.

UR - http://www.scopus.com/inward/record.url?scp=70450247016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450247016&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.058065

DO - 10.1074/jbc.M109.058065

M3 - Article

VL - 284

SP - 32610

EP - 32618

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 47

ER -